Additionally, for OBC patients, we observed that TP53 mutations conferred increased lymph node metastasis, while PIK3CA mutations appeared to be associated with chest wall metastasis in K-MASTER patients, highlighting a potential therapeutic opportunity for PI3K-mediated therapy [56]. This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.